U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
Revolution Medicines received FDA approval for RASONQUE as the first broad RAS-targeted medicine for metastatic pancreatic adenocarcinoma. The approval is supported by Phase 3 data demonstrating a 60% reduction in the risk of death and a median overall survival of 13.2 months versus 6.7 months for chemotherapy. RASONQUE is available immediately in the U.S.
Key figures
- Drug Name
- RASONQUE (daraxonrasib)
- Phase Of Trial
- Phase 3
- Dosage
- 300 mg once-daily
- Os hazard ratio
- 0.4
- Median os months
- 13.2
- Pfs hazard ratio
- 0.49
- Median pfs months
- 7.2
- Risk reduction percent
- 60
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.